Amicogen, Inc. (KOSDAQ:092040)

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Special Enzymes, New Bio Materials, Biopharmaceutical Material, Health and Beauty			55.18B	48.67B	47.13B	53.38B	69.62B
Special Enzymes, New Bio Materials, Biopharmaceutical Material, Health and Beauty Growth			13.37%	3.28%	-11.71%	-23.33%	-
Treatment for Incurable and Rare Diseases			-	-	22.93M	10.09M	-
Treatment for Incurable and Rare Diseases Growth			-	-	127.14%	-	-
Raw Drug Substance			120.22B	107.27B	85.93B	74.05B	62.67B
Raw Drug Substance Growth			12.08%	24.83%	16.04%	18.15%	-
Consolidation Adjustment			-15.50B	-11.65B	-8.20B	-11.58B	-17.11B
Total			159.90B	144.30B	124.88B	115.86B	115.18B
Total Growth			10.82%	15.55%	7.79%	0.59%	21.86%

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
South Korea			27.04B	28.21B	95.65B	83.87B	72.32B
South Korea Growth			-4.15%	-70.51%	14.04%	15.98%	-
Overseas			132.87B	116.09B	29.23B	31.98B	42.86B
Overseas Growth			14.45%	297.10%	-8.59%	-25.39%	-
Total			159.90B	144.30B	124.88B	115.86B	115.18B
Total Growth			10.82%	15.55%	7.79%	0.59%	-

Source: S&P Global Market Intelligence.